Market research
POAI Predictive Oncology Inc
NASDAQ USD Technology
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- 1.35
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Technology
- Industry
- Software - Infrastructure
- ISIN
- US74039M3097
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- 1.35
About
About Predictive Oncology Inc
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the POAI discussion.
5 years, 4 months ago
Predictive Oncology Inc is currently in a long term uptrend where the price is trading 9.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.0.
Predictive Oncology Inc's total revenue sank by 15.5% to $294K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-11K since the same quarter in the previous year.
Finally, its free cash flow grew by 12.9% to $-2M since the same quarter in the previous year.
Based on the above factors, Predictive Oncology Inc gets an overall score of 4/5.